首页 | 本学科首页   官方微博 | 高级检索  
检索        


Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy
Authors:Michael Rink  Emily C Zabor  Helena Furberg  Evanguelos Xylinas  Behfar Ehdaie  Giacomo Novara  Marko Babjuk  Armin Pycha  Yair Lotan  Quoc-Dien Trinh  Felix K Chun  Richard K Lee  Pierre I Karakiewicz  Margit Fisch  Brian D Robinson  Douglas S Scherr  Shahrokh F Shariat
Institution:1. Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA;2. Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;3. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA;4. Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France;5. Department of Urology, University of Padua, Padua, Italy;6. Department of Urology, Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic;g Department of Urology, General Hospital of Bolzano, Bolzano, Italy;h Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA;i Department of Urology, University of Montreal, Montreal, QC, Canada;j Department of Pathology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA;k Division of Medical Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA
Abstract:

Background

Cigarette smoking is the best-established risk factor for urothelial carcinoma development.

Objective

To elucidate the association of pretreatment smoking status, cumulative exposure, and time since smoking cessation on outcomes of patients with urothelial carcinoma of the bladder (UCB) treated with radical cystectomy (RC).

Design, setting, and participants

We retrospectively collected clinicopathologic and smoking variables, including smoking status, number of cigarettes per day (CPD), duration in years, and time since smoking cessation, for 1506 patients treated with RC for UCB. Lifetime cumulative smoking exposure was categorized as light short-term (≤20 CPD for ≤20 yr), light long-term (≤20 CPD for >20 yr), heavy short-term (>20 CPD for ≤20 yr), and heavy long-term (>20 CPD for >20 yr).

Intervention

RC and bilateral lymph node (LN) dissection without neoadjuvant chemotherapy.

Outcome measurements and statistical analysis

Logistic regression and competing risk analyses assessed the association of smoking with disease recurrence, cancer-specific mortality, and overall mortality.

Results and limitations

There was no difference in clinicopathologic factors between patients who had never smoked (20%), former smokers (46%), and current smokers (34%). Smoking status was associated with the cumulative incidence of disease recurrence (p = 0.004) and cancer-specific mortality (p = 0.016) in univariable analyses and with disease recurrence in multivariable analysis (p = 0.02); current smokers had the highest cumulative incidences. Among ever smokers, cumulative smoking exposure was associated with advanced tumor stages (p < 0.001), LN metastasis (p = 0.002), disease recurrence (p < 0.001), cancer-specific mortality (p = 0.001), and overall mortality (p = 0.037) in multivariable analyses that adjusted for standard characteristics; heavy long-term smokers had the worst outcomes, followed by light long-term, heavy short-term, and light short-term smokers. Smoking cessation ≥10 yr mitigated the risk of disease recurrence (hazard ratio HR]: 0.44; p < 0.001), cancer-specific mortality (HR: 0.42; p < 0.001), and overall mortality (HR: 0.69; p = 0.012) in multivariable analyses. The study is limited by its retrospective nature.

Conclusions

Smoking is associated with worse prognosis after RC for UCB. This association seems to be dose-dependent, and its effects are mitigated by >10 yr smoking cessation. Health care practitioners should counsel smokers regarding the detrimental effects of smoking and the benefits of smoking cessation on UCB etiology and prognosis.
Keywords:Smoking  Urothelial carcinoma  Muscle-invasive bladder cancer  Recurrence  Progression  Survival  Dose response  Radical cystectomy
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号